DS-8201a / trastuzumab deruxtecan
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DS-8201a / trastuzumab deruxtecan, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial [Phase 1]